Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Astellas Pharma Inc
A 1 arm study to assess the pharmacokinetics, and long-term safety and effectiveness of a modified release tacrolimus based immunosuppression regimen in stable pediatric liver transplant patients converted from a Prograf® based immunosuppression regimen.
Age
0–12
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patient is currently receiving Prograf® based immunosuppressive therapy for liver transplantation.
Patient has stable whole blood trough level concentrations of Prograf® and is clinically stable
You may not be if
Patient has previously received an organ transplant other than a liver
Patient is currently receiving sirolimus immunosuppression therapy.
